100 related articles for article (PubMed ID: 33367515)
1. A novel approach for monitoring TGF-β signaling in vivo in colon cancer.
Zhang BH; Wang C; Dong W; Chen X; Leng C; Luo X; Dong SL; Yin P; Zhang BX; Datta PK; Chen XP
Carcinogenesis; 2021 Apr; 42(4):631-639. PubMed ID: 33367515
[TBL] [Abstract][Full Text] [Related]
2. Antimetastatic role of Smad4 signaling in colorectal cancer.
Zhang B; Halder SK; Kashikar ND; Cho YJ; Datta A; Gorden DL; Datta PK
Gastroenterology; 2010 Mar; 138(3):969-80.e1-3. PubMed ID: 19909744
[TBL] [Abstract][Full Text] [Related]
3. Targeting transforming growth factor-beta signaling in liver metastasis of colon cancer.
Zhang B; Halder SK; Zhang S; Datta PK
Cancer Lett; 2009 May; 277(1):114-20. PubMed ID: 19147275
[TBL] [Abstract][Full Text] [Related]
4. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.
Melisi D; Ishiyama S; Sclabas GM; Fleming JB; Xia Q; Tortora G; Abbruzzese JL; Chiao PJ
Mol Cancer Ther; 2008 Apr; 7(4):829-40. PubMed ID: 18413796
[TBL] [Abstract][Full Text] [Related]
5. Distinct roles of transforming growth factor-β signaling and transforming growth factor-β receptor inhibitor SB431542 in the regulation of p21 expression.
Koo BH; Kim Y; Je Cho Y; Kim DS
Eur J Pharmacol; 2015 Oct; 764():413-423. PubMed ID: 26187313
[TBL] [Abstract][Full Text] [Related]
6. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.
Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE
Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998
[TBL] [Abstract][Full Text] [Related]
7. Effect of transforming growth factor beta (TGF-β) receptor I kinase inhibitor on prostate cancer bone growth.
Wan X; Li ZG; Yingling JM; Yang J; Starbuck MW; Ravoori MK; Kundra V; Vazquez E; Navone NM
Bone; 2012 Mar; 50(3):695-703. PubMed ID: 22173053
[TBL] [Abstract][Full Text] [Related]
8. LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells.
Gao Y; Shan N; Zhao C; Wang Y; Xu F; Li J; Yu X; Gao L; Yi Z
Int J Clin Exp Pathol; 2015; 8(5):4923-32. PubMed ID: 26191185
[TBL] [Abstract][Full Text] [Related]
9. A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers.
Halder SK; Beauchamp RD; Datta PK
Neoplasia; 2005 May; 7(5):509-21. PubMed ID: 15967103
[TBL] [Abstract][Full Text] [Related]
10. TGF-β receptor inhibitor LY2109761 enhances the radiosensitivity of gastric cancer by inactivating the TGF-β/SMAD4 signaling pathway.
Yang T; Huang T; Zhang D; Wang M; Wu B; Shang Y; Sattar S; Ding L; Liu Y; Jiang H; Liang Y; Zhou F; Wei Y
Aging (Albany NY); 2019 Oct; 11(20):8892-8910. PubMed ID: 31631064
[TBL] [Abstract][Full Text] [Related]
11. Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TβRI/II kinase inhibition with LY2109761.
Connolly EC; Saunier EF; Quigley D; Luu MT; De Sapio A; Hann B; Yingling JM; Akhurst RJ
Cancer Res; 2011 Mar; 71(6):2339-49. PubMed ID: 21282335
[TBL] [Abstract][Full Text] [Related]
12. Effects of transforming growth factor-β inhibitor on the proliferation of glioma stem/progenitor cell.
Zhang Q; Guo W; Di C; Lou M; Li H; Zhao Y
Pol J Pathol; 2017; 68(4):312-317. PubMed ID: 29517201
[TBL] [Abstract][Full Text] [Related]
13. Isothiocyanate sulforaphane inhibits protooncogenic ornithine decarboxylase activity in colorectal cancer cells via induction of the TGF-β/Smad signaling pathway.
Kaminski BM; Loitsch SM; Ochs MJ; Reuter KC; Steinhilber D; Stein J; Ulrich S
Mol Nutr Food Res; 2010 Oct; 54(10):1486-96. PubMed ID: 20603835
[TBL] [Abstract][Full Text] [Related]
14. Targeting the Transforming Growth Factor-beta pathway inhibits human basal-like breast cancer metastasis.
Ganapathy V; Ge R; Grazioli A; Xie W; Banach-Petrosky W; Kang Y; Lonning S; McPherson J; Yingling JM; Biswas S; Mundy GR; Reiss M
Mol Cancer; 2010 May; 9():122. PubMed ID: 20504320
[TBL] [Abstract][Full Text] [Related]
15. The Src family kinase inhibitors PP2 and PP1 block TGF-beta1-mediated cellular responses by direct and differential inhibition of type I and type II TGF-beta receptors.
Ungefroren H; Sebens S; Groth S; Gieseler F; Fändrich F
Curr Cancer Drug Targets; 2011 May; 11(4):524-35. PubMed ID: 21395548
[TBL] [Abstract][Full Text] [Related]
16. Contextual effects of transforming growth factor beta on the tumorigenicity of human colon carcinoma cells.
Ye SC; Foster JM; Li W; Liang J; Zborowska E; Venkateswarlu S; Gong J; Brattain MG; Willson JK
Cancer Res; 1999 Sep; 59(18):4725-31. PubMed ID: 10493532
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of Smad2 inhibits proliferation of gingival epithelial cells.
Shimoe M; Yamamoto T; Shiomi N; Tomikawa K; Hongo S; Yamashiro K; Yamaguchi T; Maeda H; Takashiba S
J Periodontal Res; 2014 Jun; 49(3):290-8. PubMed ID: 23738652
[TBL] [Abstract][Full Text] [Related]
18. TGF-β/Smads Signaling Affects Radiation Response and Prolongs Survival by Regulating DNA Repair Genes in Malignant Glioma.
Tao S; Liu M; Shen D; Zhang W; Wang T; Bai Y
DNA Cell Biol; 2018 Nov; 37(11):909-916. PubMed ID: 30230914
[TBL] [Abstract][Full Text] [Related]
19. TGF-β signaling promotes tube-structure-forming growth in pancreatic duct adenocarcinoma.
Yamaguchi T; Ikehara S; Akimoto Y; Nakanishi H; Kume M; Yamamoto K; Ohara O; Ikehara Y
Sci Rep; 2019 Aug; 9(1):11247. PubMed ID: 31375695
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature.
Kano MR; Komuta Y; Iwata C; Oka M; Shirai YT; Morishita Y; Ouchi Y; Kataoka K; Miyazono K
Cancer Sci; 2009 Jan; 100(1):173-80. PubMed ID: 19037999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
